EX-23 2 dsgn-ex23_1.htm EX-23.1 EX-23

 

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

(1)
Registration Statement (Form S-8 No. 333-254794) pertaining to the 2018 Equity Incentive Plan (Prior Plan), 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan of Design Therapeutics, Inc.,

 

(2)
Registration Statement (Form S-8 No. 333-263427) pertaining to the 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan of Design Therapeutics, Inc., and

 

(3)
Registration Statement (Form S-3 No. 333-264521) of Design Therapeutics, Inc.

 

 

of our report dated March 14, 2023, with respect to the financial statements of Design Therapeutics, Inc., included in this Annual Report (Form 10-K) of Design Therapeutics, Inc. for the year ended December 31, 2022.

 

/s/ Ernst & Young LLP

San Diego, California

March 14, 2023